top of page

elevated DHT
Dihydrotestosterone (DHT) is a highly potent reproductive hormone synthesized from testosterone, via the action of the enzyme 5α-reductase. While testosterone is primarily produced in the testes in males and to a lesser extent in the ovaries and adrenal glands in females, its conversion to DHT occurs locally within various tissues in both sexes, including the skin, scalp, and liver, as well as the prostate in men.
Within these tissues, DHT exhibits approximately 10 times greater affinity for androgen receptors compared to testosterone, making it significantly more biologically active and more effective at triggering cellular changes. In males, DHT contributes to the development of sexual characteristics, body composition, and physical strength. In both sexes, it plays a role in regulating oil production in the skin and scalp, maintaining muscle mass, and supporting libido.
DHT is a natural and necessary hormone to some extent, but when the conversion of testosterone to DHT becomes excessive, it can have several negative effects in both men and women. These include conditions such as hair loss - androgenetic alopecia, oily skin and scalp, acne, and for men specifically, benign prostatic hyperplasia.
It is also important to recognize that these conditions may occur independently of one another. This is because symptoms are dependent on the exact site of DHT activity, and the specific enzyme form of 5α-reductase involved in the conversion process. There are two enzyme types involved, both differ in their tissue distribution and functional roles. These differences influence how testosterone is converted to DHT in specific tissues, ultimately determining the precise physiological outcome.
5-Alpha-Reductase Type 1 (5αR1)
-
Location: Primarily expressed in the sebaceous glands of the skin, and the scalp
-
Role: Stimulates sebum / oil production, contributes to hair follicle miniaturization
-
Clinical Relevance: Targeted in oily skin and scalp, acne and DHT associated hair loss
5-Alpha-Reductase Type 2 (5αR2)
-
Location: Primarily expressed in the prostate, hair follicles and genital skin
-
Role: Develops male sex characteristics, maintains prostate function and growth, contributes to hair follicle miniaturization
-
Clinical Relevance: Targeted in DHT associated hair loss and benign prostatic hyperplasia [17][36]
For treatment, modulating the activity of these enzymes is fundamental to maintaining balanced DHT production. However, beyond enzymatic inhibition, an additional layer of control involves modulating the bioavailability of DHT. This is achieved through its binding to sex hormone-binding globulin (SHBG), a glycoprotein produced by the liver that sequesters circulating DHT and limits its free, biologically active capacity.
Enhancing SHBG concentrations serves as a complementary strategy to reduce DHT’s interaction with receptors, thereby attenuating its tissue-specific effects without altering total systemic androgen levels.
signs & symptoms
Hair Loss
Hair loss associated with dihydrotestosterone (DHT) is known as androgenetic alopecia (AGA), a condition that affects up to 50% of both men and women. AGA is a progressive and persistent disorder that gradually worsens over time. It is characterized by follicular miniaturization, a process in which hair follicles shrink, causing thick terminal hairs to become progressively finer. Additionally, the affected follicles spend less time in the active growth phase (anagen), resulting in shorter hair strands. In some cases, hair near the scalp may appear normal but fails to reach its previous length, leading to wispy, thinned-out ends.
The regions of hair loss are also sex-specific. In men, it follows the Norwood-Hamilton pattern, typically beginning with recession at the temples and thinning at the crown. Over time, these areas may progressively expand and merge, often resulting in significant or complete baldness in affected regions.[14]
In women it is referred to as the Ludwig pattern, which presents as progressive hair thinning in the frontal area of the scalp, particularly along the part line, increasing the spacing between hairs which gradually makes the scalp more visible, while the back of the head generally retains greater hair density.[15]
Men: Benign prostatic hyperplasia (BPH) / Prostate enlargement
Benign prostatic hyperplasia (BPH) is enlargement of the prostate, which is a condition associated with ageing and is estimated to affect 70% of men. Symptoms of BPH include poor urinary flow and straining, sensation of incomplete bladder emptying, nocturia (waking at night to void the bladder) and terminal dribbling.
Behind BPH development is DHT, which is a critical mediator of prostatic growth and has to be present for BPH to occur. For this reason medical treatments for BPH include 5α-reductase inhibitors, which suppress the formation of dihydrotestosterone (DHT) from testosterone.[3]
Oily Skin + Clogged Pores
Sebaceous glands contain 5α-reductase type 1, converting testosterone into DHT locally. As a result, blood tests may show normal or low DHT levels even when significant hormonal activity is occurring at the tissue level.
DHT plays a central role in the development of oily skin and clogged pores. It binds to androgen receptors in sebocytes, the specialized cells within sebaceous glands, stimulating excessive sebum / oil production. This overproduction of sebum combines with dead skin cells and keratin, leading to blocked pores and the formation of comedones such as blackheads and whiteheads. [1]
Acne
-
Chin
-
Lower Cheeks and Jawline
-
Perioral / Mouth area
-
Neck
Acne associated with DHT has been demonstrated to preferentially affect the lower third of the face including the lower cheeks, jawline, chin, neck, and upper back because these regions contain the highest density of androgen receptors [51]. DHT related acne can also coincide with elevated Testosterone related acne, which has more affinity for the oily T zones such as the forehead and nose.
In the circumstance of DHT related acne, DHT binds to its receptors and excess sebum is created, which creates an ideal environment for colonization by Cutibacterium acnes, central in the development of acne. Beyond stimulating sebum production, DHT also promotes inflammation by increasing the expression of proinflammatory cytokines in sebocytes. These cytokines promote local inflammation and immune cell recruitment, worsening the clogging and irritation of pores.[1][2]
Causes
Psychological Stress [ Hypercortisolism ]
-
Enhanced expression and sensitivity of DHT receptors in hair follicle cells
-
Increases 5α-reductase, Type 1
Chronic psychological stress leads to sustained elevations in cortisol, when cortisol remains elevated over time, it disrupts the normal signaling of the HPG axis, which governs sex hormone production and feedback regulation. This dysregulation has been shown to inadvertently shift metabolism in a way that favors 5α-reductase type 1, and subsequent DHT accumulation.
Concurrently, stress and cortisol signaling also enhances the expression and sensitivity of androgen receptors (ARs) in hair follicle cells, creating heightened receptor sensitivity and a permissive environment for accelerated follicular miniaturization and hair loss in response to DHT. [23]
Elevated Insulin [ Impaired Glucose Tolerance ]
-
Increases 5α-reductase, Type 1
Research shows that insulin spikes associated with high sugar consumption or impaired glucose metabolism significantly increase the activity of 5α-reductase, particularly Type 1 (5αR1), involved in oily skin, hair and acne.
One study demonstrated that between both men and women, higher fasting insulin, increased 5α-reductase activity by approximately 30 - 50%, depending on sex. Another study demonstrated that insulin directly increased the amount of genetic material (mRNA) used to make the 5α-reductase type 1 enzyme within ovarian cells. When insulin was elevated, it doubled 5αR1 within 6 hours, and increased significantly within 12 hours. Whereas no appreciable expression of 5α-reductase type 2 was detected.[18][19]
Overweight Status
-
Increases 5α-reductase, Type 1
In circumstances of Increased body fat or obesity, the body processes the hormone cortisol differently. Specifically, cortisol is more favourably broken down via the 5α-reduction pathway, which is carried out by the enzyme 5α-reductase type 1 (5αR1), rather than the normal 5β-reduction pathway.
This increase in 5α-reductase appears to be the body's way of protecting itself from the harmful metabolic effects of too much active cortisol, increasing glucose production, fat storage, and insulin resistance in an already compromised position. The byproduct of this is decreased cortisol but elevated DHT.[20]
Genetic Disposition
-
Increases 5α-reductase, Type 2
A genetic polymorphism in the SRD5A2 gene results in a change in the 5α-reductase type 2 enzyme, which increases its activity, allowing it to convert testosterone to dihydrotestosterone (DHT) more efficiently.
This leads to higher local DHT levels in tissues such as the prostate, skin, and hair follicles. Clinically, this gene polymorphism has been linked to increased risk or severity of conditions like benign prostatic hyperplasia (BPH), prostate cancer, and male pattern baldness.[22]
Female Hormone Disorders
Since DHT is converted from the precursor Testosterone, all hormonal imbalances that correlate to high testosterone production naturally contribute to high DHT, if the enzyme 5α-reductase activity is not limited. For women these imbalances include:
-
Polycystic Ovaries (PCO)
-
Polycystic Ovarian Syndrome (PCOS)
-
Increased LH:FSH Ratio
-
Progesterone Deficiency
-
Elevated Prolactin
-
Aromatase Deficiency
Low Sex Hormone Binding Globulin (SHGB)
SHBG is a plasma glycoprotein produced by the liver that binds to DHT, limiting its bioavailability. As a result reduced SHBG levels can significantly increase the proportion of free, unbound DHT, which enhances receptor activation in target tissues such as the scalp, skin, and prostate, potentially exacerbating DHT-mediated conditions including androgenetic alopecia, acne, hirsutism, and benign prostatic hyperplasia.
In one clinical study SHBG was measured in 64 men with androgenetic alopecia and in forty males within the same age range without alopecia. The results identified a significant reduction in SHBG levels in bald men, compared with controls. [28] Another study demonstrated for every 24 nmol/L decrease of SHBG found in blood samples, it correlated with a 6.5% reduction in scalp hair density.[29]
In relation to a study on women with acne, participants were also found to have much lower levels of SHBG compared to those without acne. In women with acne only, the average SHBG level was 48 nmol/L. In those with acne plus male pattern hair growth, it dropped further to 39 nmol/L. Whereas healthy women without acne had an average SHBG level of 70 nmol/L. [30]
Further studies demonstrate the necessary balance between SHBG and DHT levels for maintaining prostate homeostasis. With disruptions of this balance, particularly when SHBG decrease by 20 nmol from standard measure, it increases the risk of benign prostate hyperplasia by approximately 33% and overall results in greater prostate instability and even increased risk of cancer development and progression.[31][32]
Factors attributing to low SHBG factors include:
-
Hypothyroidism: cases exhibiting decreased SHGB levels, approx 25% lower compared to individuals with normal thyroid function.
-
Elevated Prolactin, also driven by Dopamine Deficiency
-
Elevated Insulin, also driven by Impaired Glucose Metabolism
-
Age, with a 2.4% decrease in SHBG every year from beginning of 30’s through to 60
[25][26][27][28][33][35]
Nutritional deficiencies
Divalent metal ions play a crucial regulatory role in modulating the activity of 5α-reductase. A deficiency in these minerals may lead to unchecked 5α-reductase activity and increased DHT production. Key inhibitory minerals include:
-
Zinc
-
Copper
-
Iron [44]
References
[1] https://pubmed.ncbi.nlm.nih.gov/20043171/
[2].https://www.tandfonline.com/doi/full/10.1080/09546634.2023.2298878#abstract
[3].https://www.metagenicsinstitute.com.au/tech-data/herbal-support-prostate-health
[4].https://www.sciencedirect.com/science/article/abs/pii/S0378874111008774
[5].https://www.sciencedirect.com/science/article/abs/pii/S0014299921004040
[6].https://www.myfoodresearch.com/uploads/8/4/8/5/84855864/_1__fr-ipsb-s09_noor.pdf
[7] https://pubmed.ncbi.nlm.nih.gov/23298508/
[8] https://pmc.ncbi.nlm.nih.gov/articles/PMC6859144/
[9] https://pubmed.ncbi.nlm.nih.gov/8922564/
[10] https://pmc.ncbi.nlm.nih.gov/articles/PMC4017725/
[11] https://pubmed.ncbi.nlm.nih.gov/33544448/
[12] https://pmc.ncbi.nlm.nih.gov/articles/PMC8276191/
[13] https://pubmed.ncbi.nlm.nih.gov/36124918/
[14] https://www.ncbi.nlm.nih.gov/books/NBK430924/
[15].https://www.sciencedirect.com/science/article/pii/S0022202X15529369
[16] https://pubmed.ncbi.nlm.nih.gov/37043171/
[17] https://pmc.ncbi.nlm.nih.gov/articles/PMC1472916/
[18].https://academic.oup.com/biolreprod/article-abstract/81/Suppl_1/563/2955843
[19].https://www.endocrine-abstracts.org/ea/0015/ea0015p158
[20].https://joe.bioscientifica.com/view/journals/joe/212/2/111.xml
[21] https://pubmed.ncbi.nlm.nih.gov/7229982/
[22] https://onlinelibrary.wiley.com/doi/10.1155/2012/530121
[23] https://pmc.ncbi.nlm.nih.gov/articles/PMC11514570/
[24] https://pubmed.ncbi.nlm.nih.gov/18479901/
[25] https://pubmed.ncbi.nlm.nih.gov/7749500/
[26] https://pubmed.ncbi.nlm.nih.gov/3346353/
[27].https://www.sciencedirect.com/science/article/abs/pii/0009898177902765
[28] https://pubmed.ncbi.nlm.nih.gov/6684473/
[29] https://pmc.ncbi.nlm.nih.gov/articles/PMC10517678/
[30] https://pubmed.ncbi.nlm.nih.gov/6458423/
[31].https://www.sciencedirect.com/science/article/abs/pii/S0960076024001547
[32].https://dmsjournal.biomedcentral.com/articles/10.1186/s13098-015-0089-1
[33] https://pmc.ncbi.nlm.nih.gov/articles/PMC3853872/
[34] https://www.mdpi.com/1422-0067/26/3/1261
[35] https://pmc.ncbi.nlm.nih.gov/articles/PMC2648802/
[36] https://pubmed.ncbi.nlm.nih.gov/10583052/
[37] https://pmc.ncbi.nlm.nih.gov/articles/PMC8527717/
[38] https://pmc.ncbi.nlm.nih.gov/articles/PMC2809240/
[39] https://pmc.ncbi.nlm.nih.gov/articles/PMC2809240/
[40] https://www.researchgate.net/publication/325575102
[41] https://www.mdpi.com/2072-6643/12/1/153
[42] https://pmc.ncbi.nlm.nih.gov/articles/PMC7424038/
[43].https://academic.oup.com/jnci/article-abstract/95/13/1004/2520319?redirectedFrom=fulltext
[44] https://pubmed.ncbi.nlm.nih.gov/7738354/
[45] https://pmc.ncbi.nlm.nih.gov/articles/PMC6124235/
[46] https://pmc.ncbi.nlm.nih.gov/articles/PMC4120804/
[47].https://trichopartner.pl/wp-content/uploads/2025/02/kwon2007.pdf?srsltid=AfmBOoq0tT1788qIIV6kHEhB891jN8ShpVoQwuUUeF8GhTMFOEMgTtuU
[48] https://pubmed.ncbi.nlm.nih.gov/18308079/
[49] https://www.tjpr.org/admin/12389900798187/2022_21_4_18.pdf
[50] https://pmc.ncbi.nlm.nih.gov/articles/PMC10749388/

bottom of page